ISM4312A / Insilico Medicine - LARVOL DELTA

Targeting DGKA for immuno-oncology therapy: ISM4312A, a novel DGKA inhibitor with robust anti-tumor activity (AACR 2023) - "Data from this combination study indicate synergistic activity as compared with the single anti-PD-1 treatment (TGI, 50.8% at 5 mg/kg BID, no mice achieved CR). ISM4312A also exhibited favorable ADME, excellent oral bioavailability, and tolerance.Together, the data support the ongoing clinical development of ISM4312A as a potential first-in-class DGKA inhibitor in cancer immunotherapy."

Immuno-oncology • Oncology • IL2